Why It Matters
Jazz Pharmaceuticals Inc. is significantly bolstering its lobbying arsenal at a moment of intensifying pressure on the pharmaceutical industry. The Trump administration’s May 2025 executive order on Most Favored Nation drug pricing directly targets Jazz’s core business. Meanwhile, Medicare’s drug price negotiation program continues expanding, with 15 drugs successfully negotiated to 44% lower prices in November 2025.
The pharmaceutical industry is sounding alarms with record lobbying spending of $227 million in the first half of 2025 alone. Major drugmakers formed a new "IRA Watchdog" coalition in August 2025 to coordinate opposition to Medicare negotiation expansion.
By the Numbers
The company hired Nickles Group LLC in February 2025, adding three veteran healthcare lobbyists with over 16 years of combined senior-level experience on the Senate Finance, House Ways and Means, and Senate Budget committees—the precise congressional bodies shaping Medicare drug price negotiation and broader pricing reforms.
Jazz has maintained consistent federal lobbying presence since 2011, spending over $11.9 million historically. The new Nickles Group LLC team brings three seasoned lobbyists:
Brett T. Baker has over 9 years of Capitol Hill experience, serving as Deputy Director of Health Policy on the Senate Finance Committee and as Professional Staff Member on House Ways and Means. He has represented major pharmaceutical clients including Amgen Inc. and Johnson & Johnson.
Gregory B. D’Angelo brings nearly 7 years of congressional experience, including as Professional Staff Member on the Senate Budget Committee, focusing on drug pricing and pharmacy benefit managers for clients like Amgen.
Mary Elizabeth Savary Taylor brings over two decades of healthcare lobbying experience representing the American Hospital Association and Amgen on Medicare, Medicaid, and drug pricing matters.
The Agenda
Jazz is lobbying on three core issues: prescription drug regulation, Most Favored Nation drug pricing, and cannabinoid regulation. The company faces sweeping congressional proposals like the Global Fairness in Drug Pricing Act and the Fair Prescription Drug Prices for Americans Act, which would tie U.S. prices to international benchmarks.
On cannabinoids, Jazz has a unique stake: the company markets Epidiolex®, the FDA-approved plant-derived cannabinoid medicine for rare seizures, and needs clear regulatory pathways to protect that market position.
Broader Context
The pharmaceutical sector faces unprecedented political pressure. Medicare’s drug price negotiation program continues expanding, while federal courts have upheld the program despite industry opposition.
For Jazz specifically, the company’s specialty focus on cannabinoid-derived medicines creates distinct regulatory challenges. While Epidiolex remains the only FDA-approved human drug derived from cannabis, the broader CBD market faces increased scrutiny. Jazz’s lobbying likely aims to maintain Epidiolex’s pharmaceutical status while preventing regulatory confusion with unregulated supplements.
Between The Lines
Congress is actively moving on all three issues central to Jazz’s lobbying push. Multiple bills establish Most Favored Nation pricing models, including H.R.3493 and S.1587. Senator Amy Klobuchar’s SMART Prices Act would increase drugs subject to negotiation.
Medicare drug negotiation continues expanding, with Senator Jacky Rosen announcing 15 additional drugs selected for negotiation. H.R.1492 seeks to equalize negotiation periods between small-molecule drugs and biologics.
Competitive Landscape
Jazz enters a highly competitive lobbying environment. Amgen, Bristol-Myers Squibb, and Genentech are heavily engaged on identical issues. PhRMA spent a record $12.9 million on lobbying in Q1 2025 alone.
This coordinated opposition comes amid significant policy momentum. President Trump signed an executive order on May 12, 2025, directing implementation of Most Favored Nation drug pricing, while Medicare negotiations delivered real results with some drugs seeing 71% price reductions.
The Bottom Line
Jazz is significantly expanding its Washington influence through sophisticated, committee-level advocacy to shape emerging policy frameworks. The company’s specific interest in cannabinoid regulation protects its FDA-approved Epidiolex product amid broader regulatory uncertainty.
Access the Legis1 platform for comprehensive political news, data, and insights.
Spot something wrong? Report an issue with this article